Abstract
In the modern combined modality setting radiotherapy needs only be given to the initially involved tissue volume. Radiation fields have therefore become much smaller. This treatment approach makes highly accurate target definition mandatory. With the implementation of advanced imaging, especially PET/CT, and image co-registration, it is now possible to contour the initially involved tissue volume very accurately on the post-chemotherapy planning CT scan. Meticulous and systematic analysis of the pre- and post-chemotherapy scans and adherence to stringent criteria are necessary for the proper implementation of this technique, called involved node radiotherapy (INRT).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al (2003) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21:3431–3439
Berthelsen AK, Holm S, Loft A et al (2005) PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 32:1167–1175
Bhatia S, Robison LL, Oberlin O et al (1996) Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 334:745–751
Biti GP, Cimino G, Cartoni C et al (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I–IIA Hodgkin’s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 10:378–382
Bonadonna G, Bonfante V, Viviani S et al (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22:2835–2841
Castellino RA, Hoppe RT, Blank N et al (1984) Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin disease. AJR Am J Roentgenol 143:37–41
Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244–1253
Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586
Donaldson SS, Link MP, Weinstein HJ et al (2007) Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin’s disease. J Clin Oncol 25:332–337
Girinsky T, van der Maazen R, Specht L et al (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277
Girinsky T, Ghalibafian M, Bonniaud G et al (2007) Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol 85:178–186
Girinsky T, Specht L, Ghalibafian M et al (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88:202–210
Guermazi A (2001) Is it wise to eliminate lymphography from the staging of Hodgkin’s disease? Leuk Lymphoma 42:655–660
Hancock SL, Tucker MA, Hoppe RT (1993) Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 270:1949–1955
Hanna SL, Fletcher BD, Boulden TF et al (1993) MR imaging of infradiaphragmatic lymphadenopathy in children and adolescents with Hodgkin disease: comparison with lymphography and CT. J Magn Reson Imaging 3:461–470
Hutchings M, Loft A, Hansen M et al (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 78:206–212
ICRU (1993) Prescribing, recording and reporting photon beam therapy. Report 50
ICRU (1999) Prescribing, recording and reporting photon beam therapy. Report 62
Kyzas PA, Evangelou E, Denaxa-Kyza D et al (2008) 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 100:712–720
Landman-Parker J, Pacquement H, Leblanc T et al (2000) Localized childhood Hodgkin’s disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 18:1500–1507
Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636
Longo DL, Glatstein E, Duffey PL et al (1991) Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin’s disease: seven-year results of a prospective randomized trial. J Clin Oncol 9:906–917
Mauch P (1995) Second malignancies after curative radiation therapy for good prognosis cancers. Int J Radiat Oncol Biol Phys 33:959–960
Ng AK, Bernardo MP, Weller E et al (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 20:2101–2108
Pavlovsky S, Maschio M, Santarelli MT et al (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I–II Hodgkin’s disease. J Natl Cancer Inst 80:1466–1473
Shahidi M, Kamangari N, Ashley S et al (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78:1–5
Specht L (2007) 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol 17:190–197
Valette F, Querellou S, Oudoux A et al (2007) Comparison of positron emission tomography and lymphangiography in the diagnosis of infradiaphragmatic Hodgkin’s disease. Acta Radiol 48:59–63
van Leeuwen FE, Klokman WJ, Stovall M et al (2003) Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 95:971–980
Acknowledgements
Lorna Saint Ange for editing the chapter, Claude Ruelle for help with the web-based quality assurance program, Dosisoft (Cachan 92000, France) for providing the software to analyze the imaging procedures and contourings from all major cancer centers, Etiam for providing the installation and maintenance of the web network and servers and finally the Clarence Westbury Foundation for financial assistance.
Laurence Gonzague M.D., Karine Peignaux M.D., Sawyna Provencher, M.D. Juliette Thariat M.D., Françoise Izar M.D., Bernard Dubray M.D., Christine Kerr M.D., Claire Brunaud M.D., Loic Feuvret M.D., Floriane Toudic M.D., Georges Noel M.D., Jean Leon Lagrange M.D. for providing patient data.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Girinsky, T., Ghalibafian, M., Specht, L. (2011). Target Definitions for Hodgkin Lymphoma: The Involved Node Radiation Field Concept. In: Specht, L., Yahalom, J. (eds) Radiotherapy for Hodgkin Lymphoma. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78944-4_9
Download citation
DOI: https://doi.org/10.1007/978-3-540-78944-4_9
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-78455-5
Online ISBN: 978-3-540-78944-4
eBook Packages: MedicineMedicine (R0)